Genedata
Genedata sells software for biopharma research and development, from discovery screening through translational studies and manufacturing development, and counts Pfizer, Sanofi, Amgen, Lilly, GSK, AstraZeneca, Roche, Novartis and Takeda among its customers. Screener brings assay measurements and metadata from instruments into shared analytics and reporting, with deep learning to classify screening images and a classifier that picks the analysis model for an assay. Profiler brings clinical, imaging and molecular data into a research workspace, where its Biomarker Discovery Agent suggests analyses a scientist can review and trace back through the workflow. Biologics carries an Exploration Assistant for tracing relationships in biologics data, Selector handles sequencing data for development and biosafety testing, and a new lab notebook ties experiments and results to the project record. Vico, built on Anthropic's Claude models, organizes chemistry, manufacturing and controls data. The suite runs in customer operated installations or as an AWS hosted service.
Washington University School of Medicine in St. Louis used Profiler to identify a five protein blood biomarker model for Alzheimer's disease and tested it in an independent cohort. Merck reported a threefold acceleration after automating data loading, analysis, quality control and reporting with Screener, and Pfizer runs the platform across six research sites with more than 250 users on more than 200 projects.
Othmar Pfannes founded Genedata in 1997 in Basel, Switzerland, and the company is part of Danaher.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
Genedata Imagence interprets images from screening assays, Screener's learned classifier picks the analysis model for an assay, and Profiler's Biomarker Discovery Agent proposes analyses from a researcher's question and the data available to answer it. Biologics adds an Exploration Assistant, and Vico applies Claude based reasoning to manufacturing development data.
Around them, the suite registers samples and experimental results, runs conventional statistics and routes records between instruments and researchers, and Merck's Screener deployment centers on data loading, quality control and reporting. Sequencing software and a lab notebook complete a system of record that runs without the AI tools.
Profiler's agent checks whether a question suits the available data and offers the scientist options for going ahead, and every step in the resulting workflow is traceable. Regulated use runs through a validation workflow with audit logs and controls around versioned analyses, and Vico records the model versions used in manufacturing development, so staff can review how any analysis was done. Which operations the agent may run without a specific approval, and whether it stops when a proposed analysis lacks enough information, are not stated.
Deep learning drives image analysis in Screener and Imagence, and an assay classifier picks a fitting model for each set of measurements. Profiler's agent uses natural language to propose analyses of structured clinical and molecular data. Anthropic's Claude family is named as the foundation of Vico's scientific reasoning, in the manufacturing development product, and Vico tracks the versions of models used in a customer workflow. The models behind Profiler's assistant and the prebuilt vision classifiers, their training sets and their release schedule are not named.
Anthropic supplies the Claude models named for Vico's reasoning, while Genedata runs the workflow and lets customers bring other models into the environment. Amazon Web Services hosts the managed software, installations can also run in customer facilities, and the image analysis models are Genedata's own.
No provider is named for Profiler's biomarker assistant or the Biologics Exploration Assistant, nothing says whether a local installation calls a remote service for each AI feature, and no single list covers processors, retention periods or model training terms across the suite.
A Washington University and Danaher research collaboration used the Profiler agent to identify a five protein model for Alzheimer's disease. Its November 2026 poster draws on plasma proteomic data from nearly 3,000 participants and reports validation in an independent external cohort, with an improvement over a single biomarker approach stated without its size.
Merck reported a threefold acceleration after automating a Screener workflow from data loading through reporting, a measure of the whole workflow rather than the AI steps. Pfizer describes its use across six research sites. The Alzheimer's result is research and does not stand as evidence for a diagnostic in routine use.
Profiler works with structured clinical data, omics measurements and imaging inside a controlled analytics environment, with access limited by role and separate environments for AI workloads. The privacy notice explains how Genedata treats deidentified data and hands business customer health information to the customer's own notices and agreements, so the terms for identifiable data in a given Profiler installation sit in that contract. How long patient data or prompts stay in hosted AI processing, whether they can train models, and how Genedata responds to an incorrect AI output are not stated.
Profiler processes clinical and research data in translational analysis. Genedata's general privacy notice covers health information collected for research and separates it from health information processed in service for a business customer, which it leaves to separate notices and contracts, and its references to US privacy rights describe how a provider discloses health information.
No business associate position, agreement for clinical datasets or equivalent service arrangement for those records is offered, so a translational group loading identifiable cohort data meets those terms only in its own contract.
Genedata states that an independent CPA firm audits its information systems and processes and that it holds a current SOC 2 Type 2 report, and its earlier brochure extends that claim to Managed Cloud. The regulated software adds account permissions, timestamped audit records and controls over source and destination data, the hosted service runs on AWS, and some regulated installations are single tenant. The report is not public, and its scope is not tied to the current AI services or to outside model providers. Genedata also posts security notices on vulnerabilities that affect its products.
Profiler is sold to research teams that develop and evaluate disease biomarkers, and Genedata describes how that work can lead toward approval of a separate in vitro diagnostic. The Alzheimer's collaboration evaluated a blood biomarker model in research. Auditability and validation support serve teams working under rules such as 21 CFR Part 11 and GxP.
The suite is sold for research, development and regulated laboratory operations, with no claim that the Profiler agent itself diagnoses an individual patient, and none of the AI tools carries or claims a device clearance.
Genedata keeps a timestamped history of changes to data and analytical workflows, and its regulated environments run validated workflows, version control, role permissions and segregated AI environments, with a specific module validated apart from access controls or wider system settings. In Vico, scientists can track a model as it changes and keep its results tied to the underlying data, and Profiler keeps a record of how each question was analyzed.
GxP services and validation support help a customer's quality team qualify those controls for regulated work. No results compare the AI assistants' performance across populations, assay types or data sources.
Profiler keeps a traceable path from source data through the options it proposes into the finished analysis, so a scientist can reproduce the workflow and find which step produced an unexpected result. Genedata keeps change logs and assigns a contact for deployment and support.
Its website terms apply to website material and leave software obligations to commercial agreements, and nothing on the site offers an output warranty, a correction deadline or a remedy for a person affected by an error. The Alzheimer's study results are research findings rather than a service commitment.
No clinical record integration is offered for the suite; its connections run to research systems. Screener has a named catalog of instrument and software connections that bring assay data into a standard workflow, Genedata Biologics passes experiments to laboratory notebooks and information systems, and the native lab notebook ties into the experimental record. Integrated SCIEX and Genedata solutions carry mass spectrometry workflows for biotherapeutics in regulated environments. Profiler takes in clinical datasets for research, loaded as study data rather than through a live link to an EHR.
Biopharma teams run Genedata on their own premises or take a managed service on AWS, where Genedata handles upgrades and maintenance. The customer operated option keeps experimental records inside the customer's own systems, and regulated deployments can be dedicated single tenant installations. Which AWS regions hold a hosted customer's primary data and backups, and how each AI feature routes information to a model provider, are not stated. The privacy notice covers cross border safeguards for personal information and leaves customer health information to contract terms.
Products in the Biopharma Platform can be licensed one at a time or together, as customer managed software or a hosted service, with implementation, training and a GxP license with validation support for regulated use. An account buying several modules can take a hosting and implementation package, while a buyer running the software locally keeps its own infrastructure. Genedata offers a demo. No cost per user or installation, starting subscription rate, AI feature charge or service rate is shown.
Washington University School of Medicine used Profiler in neurodegenerative disease research, with its biomarker model tested in a separate cohort, and Profiler also serves inflammatory bowel disease research and other clinical and molecular datasets. Merck uses Screener for discovery workflows, Pfizer runs the platform across six research sites, and Novartis uses Vico to organize chemistry, manufacturing and controls data in SPINE Explorer. Measured results cover the Alzheimer's model and Merck's screening workflow, and the agents have not been validated by therapeutic area or for routine clinical diagnosis.
Alternatives to Genedata
Other products that do the same kind of work as Genedata, and what each one does.
LatchBio runs a cloud workspace where biotech, pharma and academic research teams store, analyze and visualize omics data, alongside an AI research lab that benchmarks how well agents analyze biological data.
BenchSci develops EMET, an AI research environment for scientists in biopharma and academia. The platform combines scientific literature, experimental databases and internal research with a biomedical knowledge graph.
Tissue intelligence company for drug development, applying computer vision and machine learning to H&E, immunohistochemistry, multiplex imaging and spatial transcriptomics and linking tissue features to clinical outcomes.
Tech bio company building what it calls an AI scientist for biopharma research and development, combining biological reasoning models, a multimodal patient data network and agentic software.
BigHat Biosciences, founded in San Mateo, California in 2019 by Mark DePristo and Peyton Greenside, designs and engineers antibodies with machine learning tied to its own automated laboratory, starting from an existing molecule, its own or a partner's, and improving it in rounds.
Bexorg tests drugs for central nervous system diseases in donated postmortem human brains before they reach clinical trials, working for pharmaceutical and biotechnology sponsors and on its own licensed candidates.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Quote based
|
Genedata sells separate or combined enterprise software licenses with customer operated or hosted deployment. A regulated deployment can include a GxP license and validation services. | The privacy notice leaves business customer health information to the customer agreement; no business associate agreement is offered. | Implementation, training and regulated validation services are offered, with no fee shown. | Vendor Published |
A demonstration is available. No starting price, rate per user or AI usage charge is shown.